Evaluation of the efficiency of perioperative chemotherapy in the complex treatment of gastric cancer

The aim of the study is to study the effectiveness of perioperative chemotherapy in the treatment of gastric cancer and its direct effect on the results of surgical treatmentЦелью исследования является изучение эффективности периоперационной химиотерапии при раке желудка и ее непосредственного влияния на результаты хирургического лечени

СИСТЕМАТИЧЕСКАЯ И ВЫБОРОЧНАЯ МЕДИАСТИНАЛЬНАЯ ЛИМФОДИССЕКЦИЯ В КОМБИНИРОВАНОМ ЛЕЧЕНИИ НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКОГО IIIА(N2) СТАДИИ

This article  provides  results  of  combined modality  treatment of  patients with  stage IIIA(N2) non-small cells lung cancer  with systematic and selective   lymph node  dissection. Elicit that  the  selective    lymph  node  dissection is valid for  patients with  stage IIIA(N2) squamous cell carcinoma and right-sided lung cancer when we provide combined modality treatment using adjuvant radiation therapy. Carrying out that  the systematic  lymph node dissection is extend   disease-free survival and  five-year survival rate  when  we  provide combined modality  treatment for  patients with  stage IIIA(N2) squamous cell carcinoma and left-sided lung cancer.В статье  приводятся результаты комбинированного лечения  больных  немелкоклеточным раком  легкого IIIA(N2) стадии с систематической и выборочной медиастинальной лимфодиссекцией. Выявлено,  что выборочная медиастинальная лимфодиссекция  применима у пациентов с неплоскоклеточным морфологическим вариантом опухоли  и правосторонней локализации рака  легкого  IIIA(N2) стадии  в комбинированном лечении с применением адьювантной лучевой  терапии.Выполнение  систематической медиастинальной лимфодиссекции в комбинированном лечении при плоскоклеточном раке легкого и расположении опухоли в левом легком увеличивает безрецидивную и общую пятилетнюю выживаемость больных.

SYSTEMATIC AND SAMPLING MEDIASTINAL LYMPH NODE DISSECTION OF COMBINED TREATMENT OF NON-SMALL CELLS LUNG CANCER IIIA(N2) STAGE

This article  provides  results  of  combined modality  treatment of  patients with  stage IIIA(N2) non-small cells lung cancer  with systematic and selective   lymph node  dissection. Elicit that  the  selective    lymph  node  dissection is valid for  patients with  stage IIIA(N2) squamous cell carcinoma and right-sided lung cancer when we provide combined modality treatment using adjuvant radiation therapy. Carrying out that  the systematic  lymph node dissection is extend   disease-free survival and  five-year survival rate  when  we  provide combined modality  treatment for  patients with  stage IIIA(N2) squamous cell carcinoma and left-sided lung cancer

EFFECT OF THE EXTENT OF MEDIASTINAL LYMPHODISSECTION ON THE RESULTS OF COMBINED MODALITY TREATMENT FOR STAGE IIIA (N2 ) NON-SMALL CELL LUNG CANCER

Short-and long-term results of combined modality treatment with systematic (n=60) and selective (n=51) mediastinal lymphodissection were compared in 111 patients with IIIA(N2 ) stage non-small lung cancer taking into account the tumor site, histological pattern of the tumor and the extent of radical surgery. The recurrence-free survival rate was significantly higher in patients with squamous cell lung cancer who underwent systematic lymphodissection than in patients who underwent selective lymphodissection. The median disease progression-free survival was 31 months and 14.5 months and the overall 5-year survival rates were 43,4 % and 16 %, respectively (p<0,05). A significant increase in recurrence-free and overall 5-year survival rates was observed in group I patients with cancer of the left lung as compared to that observed in group II patients. Selective mediastinal lymphodissection may be the operation of choice in patients with stage IIIA(N2 ) non-small cell lung cancer and in patients with cancer of the right lung who received combined modality treatment including adjuvant radiation therapy